Literature DB >> 9326643

Phosphorylation of two regulatory tyrosine residues in the activation of Bruton's tyrosine kinase via alternative receptors.

M I Wahl1, A C Fluckiger, R M Kato, H Park, O N Witte, D J Rawlings.   

Abstract

Mutation of Bruton's tyrosine kinase (Btk) impairs B cell maturation and function and results in a clinical phenotype of X-linked agammaglobulinemia. Activation of Btk correlates with an increase in the phosphorylation of two regulatory Btk tyrosine residues. Y551 (site 1) within the Src homology type 1 (SH1) domain is transphosphorylated by the Src family tyrosine kinases. Y223 (site 2) is an autophosphorylation site within the Btk SH3 domain. Polyclonal, phosphopeptide-specific antibodies were developed to evaluate the phosphorylation of Btk sites 1 and 2. Crosslinking of the B cell antigen receptor (BCR) or the mast cell Fcepsilon receptor, or interleukin 5 receptor stimulation each induced rapid phosphorylation at Btk sites 1 and 2 in a tightly coupled manner. Btk molecules were singly and doubly tyrosine-phosphorylated. Phosphorylated Btk comprised only a small fraction (</=5%) of the total pool of Btk molecules in the BCR-activated B cells. Increased dosage of Lyn in B cells augmented BCR-induced phosphorylation at both sites. Kinetic analysis supports a sequential activation mechanism in which individual Btk molecules undergo serial transphosphorylation (site 1) then autophosphorylation (site 2), followed by successive dephosphorylation of site 1 then site 2. The phosphorylation of conserved tyrosine residues within structurally related Tec family kinases is likely to regulate their activation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9326643      PMCID: PMC23526          DOI: 10.1073/pnas.94.21.11526

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  59 in total

1.  Signal transduction in the activation of mast cells and basophils.

Authors:  E Razin; I Pecht; J Rivera
Journal:  Immunol Today       Date:  1995-08

2.  Activation of Tsk and Btk tyrosine kinases by G protein beta gamma subunits.

Authors:  S A Langhans-Rajasekaran; Y Wan; X Y Huang
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-12       Impact factor: 11.205

3.  NMR structure of the N-terminal SH3 domain of GRB2 and its complex with a proline-rich peptide from Sos.

Authors:  N Goudreau; F Cornille; M Duchesne; F Parker; B Tocqué; C Garbay; B P Roques
Journal:  Nat Struct Biol       Date:  1994-12

4.  Structure of the N-terminal SH3 domain of GRB2 complexed with a peptide from the guanine nucleotide releasing factor Sos.

Authors:  H Terasawa; D Kohda; H Hatanaka; S Tsuchiya; K Ogura; K Nagata; S Ishii; V Mandiyan; A Ullrich; J Schlessinger
Journal:  Nat Struct Biol       Date:  1994-12

5.  Regulation of CREB phosphorylation in the suprachiasmatic nucleus by light and a circadian clock.

Authors:  D D Ginty; J M Kornhauser; M A Thompson; H Bading; K E Mayo; J S Takahashi; M E Greenberg
Journal:  Science       Date:  1993-04-09       Impact factor: 47.728

6.  A monoclonal antibody against a murine CD38 homologue delivers a signal to B cells for prolongation of survival and protection against apoptosis in vitro: unresponsiveness of X-linked immunodeficient B cells.

Authors:  Y Yamashita; K Miyake; Y Kikuchi; K Takatsu; S Noda; A Kosugi; M Kimoto
Journal:  Immunology       Date:  1995-06       Impact factor: 7.397

7.  The activation of the Jak-STAT 1 signaling pathway by IL-5 in eosinophils.

Authors:  K Pazdrak; S Stafford; R Alam
Journal:  J Immunol       Date:  1995-07-01       Impact factor: 5.422

8.  The protein defective in X-linked agammaglobulinemia, Bruton's tyrosine kinase, shows increased autophosphorylation activity in vitro when isolated from cells in which the B cell receptor has been cross-linked.

Authors:  S Hinshelwood; R C Lovering; H C Genevier; R J Levinsky; C Kinnon
Journal:  Eur J Immunol       Date:  1995-04       Impact factor: 5.532

9.  Activation of Bruton's tyrosine kinase (BTK) by a point mutation in its pleckstrin homology (PH) domain.

Authors:  T Li; S Tsukada; A Satterthwaite; M H Havlik; H Park; K Takatsu; O N Witte
Journal:  Immunity       Date:  1995-05       Impact factor: 31.745

10.  The protein product of the c-cbl protooncogene is phosphorylated after B cell receptor stimulation and binds the SH3 domain of Bruton's tyrosine kinase.

Authors:  G O Cory; R C Lovering; S Hinshelwood; L MacCarthy-Morrogh; R J Levinsky; C Kinnon
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307

View more
  39 in total

Review 1.  Early B cell defects.

Authors:  H B Gaspar; M E Conley
Journal:  Clin Exp Immunol       Date:  2000-03       Impact factor: 4.330

2.  Kinase mutant Btk results in atypical X-linked agammaglobulinaemia phenotype.

Authors:  H B Gaspar; M Ferrando; I Caragol; M Hernandez; J M Bertran; X De Gracia; T Lester; C Kinnon; E Ashton; T Espanol
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

3.  Posttranscriptional regulation of Bruton's tyrosine kinase expression in antigen receptor-stimulated splenic B cells.

Authors:  S Nisitani; A B Satterthwaite; K Akashi; I L Weissman; O N Witte; M I Wahl
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

4.  A phosphorylation site in Bruton's tyrosine kinase selectively regulates B cell calcium signaling efficiency by altering phospholipase C-gamma activation.

Authors:  Shuling Guo; Gregory Z Ferl; Rajendar Deora; Mireille Riedinger; Sheng Yin; James L Kerwin; Joseph A Loo; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-16       Impact factor: 11.205

5.  In situ detection of activated Bruton's tyrosine kinase in the Ig signaling complex by phosphopeptide-specific monoclonal antibodies.

Authors:  S Nisitani; R M Kato; D J Rawlings; O N Witte; M I Wahl
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

6.  Severe B cell deficiency and disrupted splenic architecture in transgenic mice expressing the E41K mutated form of Bruton's tyrosine kinase.

Authors:  G M Dingjan; A Maas; M C Nawijn; L Smit; J S Voerman; F Grosveld; R W Hendriks
Journal:  EMBO J       Date:  1998-09-15       Impact factor: 11.598

7.  Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk.

Authors:  Xingguang Liu; Zhenzhen Zhan; Dong Li; Li Xu; Feng Ma; Peng Zhang; Hangping Yao; Xuetao Cao
Journal:  Nat Immunol       Date:  2011-03-27       Impact factor: 25.606

8.  Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI.

Authors:  Phillip L R Nicolson; Craig E Hughes; Stephanie Watson; Sophie H Nock; Alexander T Hardy; Callum N Watson; Samantha J Montague; Hayley Clifford; Aarnoud P Huissoon; Jean-Daniel Malcor; Mark R Thomas; Alice Y Pollitt; Michael G Tomlinson; Guy Pratt; Steve P Watson
Journal:  Haematologica       Date:  2018-07-19       Impact factor: 9.941

9.  Bruton's tyrosine kinase regulates immunoglobulin promoter activation in association with the transcription factor Bright.

Authors:  Jaya Rajaiya; Melissa Hatfield; Jamee C Nixon; David J Rawlings; Carol F Webb
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

Review 10.  Molecular control of steady-state dendritic cell maturation and immune homeostasis.

Authors:  Gianna Elena Hammer; Averil Ma
Journal:  Annu Rev Immunol       Date:  2013-01-17       Impact factor: 28.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.